For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

This article describes a recently initiated Phase II trial of a novel anti-tau monoclonal antibody, BMS-986446, the design ...